Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluocinolone acetonide intravitreal implant (Ocumension Biotech)
- Development stage
- Approved
- Lead developer
- ANI Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravitreal, Ophthalmic
01
Overview
Fluocinolone acetonide intravitreal implant (OT-401) is a corticosteroid-based sustained-release drug delivery system designed for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The implant provides long-term local release of fluocinolone acetonide directly into the vitreous cavity, reducing inflammation and preventing recurrence. It is developed by Ocumension Therapeutics and EyePoint Pharmaceuticals and has been approved for marketing in China and other regions for this indication[1][2][3][7].
- Brand names
- YUTIOYUTIQ
- Other names
- OT-401OT401OT 401fluocinolone acetonide intravitreal implant
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on fluocinolone acetonide intravitreal implant (Ocumension Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluocinolone acetonide intravitreal implant (Ocumension Biotech).